Shield Therapeutics Seals Japan License Agreement
Deal News | May 13, 2025 | Stephenson Harwood LLP
Stephenson Harwood LLP has played a key advisory role in the recent exclusive licensing agreement between Shield Therapeutics plc and VITAL-NET, Inc. The law firm's expert guidance facilitated Shield Therapeutics' strategic move to extend the reach of its iron deficiency treatment product, ACCRUFeR®, into the lucrative Japanese market. This deal is poised to strengthen Shield Therapeutics’ market position and expand its global footprint.
Sectors
- Pharmaceuticals
- Legal Services
Geography
- Japan – The licensing agreement is exclusive to the Japanese market.
- United Kingdom – Shield Therapeutics is based in the UK, while Stephenson Harwood LLP is a UK-based law firm.
Industry
- Pharmaceuticals – The article involves a licensing agreement for ACCRUFeR®, a pharmaceutical product, thereby placing it in the Pharmaceuticals industry.
- Legal Services – Stephenson Harwood LLP, a law firm, advised on the licensing agreement, highlighting the involvement of the Legal Services industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Shield Therapeutics plc | Target | Company | A pharmaceutical company engaging in the exclusive licensing of their product, ACCRUFeR®. |
| VITAL-NET, Inc. | Bidding Company | Company | A company entering into an exclusive license agreement for ACCRUFeR® in Japan. |
| Stephenson Harwood LLP | Legal Advisor | Company | A law firm providing legal advice for the licensing agreement. |